Monopar Therapeutics
MNPR
82.54
-1.24
-1.48%
Monopar Therapeutics
US · MNPR
#3671 by market cap
Listed 2019
82.54
-1.24
-1.48%
Live - 5344 symbols - heartbeat 346s ago
· 2026-10-08 10:00
Pre-market
84.54
+0.91%
After-hours
83.80
+0.02%
Overnight
83.03
-0.90%
- Market cap
- 554.02M
- P/E (TTM)i
- -37.52
- P/Bi
- 4.23
- EPSi
- -1.85
- Div yieldi
- 0.00%
- 52W posi
- 43%
Reader sentiment
Are you bullish or bearish on MNPR?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.56M | 2.36M | 2.44M | 2.63M | 2.95M | 3.23M | 3.16M | 6.80M |
| Research & development | 1.77M | 1.97M | 4.07M | 6.49M | 7.59M | 5.60M | 13.01M | 9.90M |
| Operating profit | -3.33M | -4.32M | -6.51M | -9.13M | -10.54M | -8.83M | -16.16M | -16.70M |
| Pretax profit | -3.23M | -4.22M | -6.30M | -9.10M | -10.52M | -8.40M | -15.59M | -13.72M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -3.23M | -4.22M | -6.30M | -9.10M | -10.52M | -8.40M | -15.59M | -13.72M |
| Basic EPS | -2 | -2 | -3 | -4 | -4 | -3 | -4 | -2 |
| Diluted EPS | -1.55 | -2.25 | -2.90 | -3.65 | -4.15 | -3.04 | -4.11 | -1.85 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.58M | 1.50M | 1.50M | 2.21M | 1.74M | 1.88M |
| Research & development | 1.64M | 1.73M | 2.59M | 3.94M | 3.49M | 4.77M |
| Operating profit | -3.22M | -3.23M | -4.09M | -6.16M | -5.23M | -6.64M |
| Pretax profit | -2.62M | -2.45M | -3.44M | -5.20M | -3.89M | -5.31M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -2.62M | -2.45M | -3.44M | -5.20M | -3.89M | -5.31M |
| Basic EPS | 0 | 0 | 0 | -1 | 0 | -1 |
| Diluted EPS | -0.38 | -0.35 | -0.48 | -0.64 | -0.46 | -0.62 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 7.25M | 13.23M | 16.80M | 20.52M | 13.17M | 7.33M | 60.29M | 140.46M |
| Cash & ST investments | 6.89M | 13.21M | 16.74M | 20.30M | 13.12M | 7.27M | 60.21M | 140.40M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 7.32M | 13.35M | 16.87M | 20.52M | 13.23M | 7.35M | 60.29M | 140.72M |
| Total current liabilities | 399.55K | 724.17K | 1.18M | 1.58M | 3.13M | 1.76M | 5.25M | 2.74M |
| Short-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 399,551.00 | 724,165.00 | 1,176,666.00 | 1,580,543.00 | 3,137,302.00 | 1,757,393.00 | 5,254,300.00 | 2,890,156.00 |
| Total equity | 6.92M | 12.63M | 15.69M | 18.94M | 10.09M | 5.59M | 55.04M | 137.83M |
| Retained earnings | -21.66M | -25.88M | -32.19M | -41.29M | -51.80M | -60.21M | -75.79M | -89.51M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 55.08M | 53.75M | 144.09M | 140.46M | 137.74M | 134.76M |
| Cash & ST investments | 54.55M | 53.25M | 143.68M | 140.40M | 137.49M | 134.30M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 55.09M | 53.87M | 144.20M | 140.72M | 137.98M | 134.98M |
| Total current liabilities | 1.49M | 1.58M | 2.57M | 2.74M | 2.46M | 4.02M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,491,960.00 | 1,663,979.00 | 2,639,430.00 | 2,890,156.00 | 2,589,313.00 | 4,123,859.00 |
| Total equity | 53.59M | 52.20M | 141.56M | 137.83M | 135.39M | 130.85M |
| Retained earnings | -78.42M | -80.87M | -84.31M | -89.51M | -93.40M | -98.72M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.68M | -3.02M | -4.66M | -7.32M | -7.23M | -7.86M | -6.40M | -12.20M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- | -- | -- |
| Free cash flow | -2.68M | -3.02M | -4.66M | -7.32M | -7.23M | -7.86M | -6.40M | -12.20M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 10.22M | 8.18M | 10.93M | 109.34K | 2.07M | 59.40M | 92.14M |
| Ending cash balance | 6.89M | 13.21M | 16.74M | 20.30M | 8.19M | 7.27M | 45.82M | 61.83M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -5.66M | -1.08M | -2.09M | -3.37M | -3.47M | -3.25M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -5.66M | -1.08M | -2.09M | -3.37M | -3.47M | -3.25M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -631.39K | -- | -- |
| Ending cash balance | 39.71M | 39.50M | 127.68M | 61.83M | 52.54M | 52.76M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -39.04 | -43.23 | -44.52 | -52.57 | -72.44 | -107.19 | -51.42 | -14.22 |
| ROA %i | -37.43 | -40.88 | -41.72 | -48.69 | -62.32 | -81.69 | -46.09 | -13.65 |
| ROIC %i | -40.26 | -44.24 | -45.10 | -52.71 | -72.55 | -112.60 | -52.75 | -17.29 |
| 5-year avg ROE %i | -- | -- | -86.92 | -89.06 | -50.36 | -63.99 | -65.63 | -59.57 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 18.15 | 18.27 | 14.28 | 12.98 | 4.21 | 4.17 | 11.47 | 51.35 |
| Quick ratioi | 17.25 | 18.25 | 14.22 | 12.85 | 4.19 | 4.13 | 11.46 | 51.33 |
| Debt / assetsi | -- | -- | -- | 0.00 | 0.06 | -- | 0.00 | 0.11 |
| LT debt / equityi | -- | -- | -- | -- | 0.08 | -- | -- | 0.11 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -54.27 | -59.38 | -26.54 | -14.22 | -15.86 | -19.50 |
| ROA %i | -51.78 | -56.71 | -25.88 | -13.65 | -15.52 | -18.90 |
| ROIC %i | -57.27 | -64.79 | -29.49 | -17.29 | -19.77 | -24.11 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 36.92 | 33.94 | 56.10 | 51.35 | 56.04 | 33.56 |
| Quick ratioi | 36.56 | 33.63 | 55.94 | 51.33 | 55.94 | 33.44 |
| Debt / assetsi | -- | 0.15 | 0.05 | 0.11 | 0.10 | 0.08 |
| LT debt / equityi | -- | 0.15 | 0.05 | 0.11 | 0.10 | 0.08 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 10:00:07 · For reference only, not investment advice and not tailored to your situation.